Matches in Nanopublications for { ?s ?p "[DKK1 methylation was found in 14 (29.8%) patients, and more frequently in those with CBF leukaemia (6 of 12 patients), than in those with acute promyelocytic leukaemia (APL) (0 of 6 patients) (P = 0.03).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP720611.RAta0UDwYYR1oA-OnlOwJwiuUZSmzmtFZT5AMf7bWcWTA130_assertion description "[DKK1 methylation was found in 14 (29.8%) patients, and more frequently in those with CBF leukaemia (6 of 12 patients), than in those with acute promyelocytic leukaemia (APL) (0 of 6 patients) (P = 0.03).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP720611.RAta0UDwYYR1oA-OnlOwJwiuUZSmzmtFZT5AMf7bWcWTA130_provenance.
- assertion description "[DKK1 methylation was found in 14 (29.8%) patients, and more frequently in those with CBF leukaemia (6 of 12 patients), than in those with acute promyelocytic leukaemia (APL) (0 of 6 patients) (P = 0.03).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP624116.RAb4fmOs9XqlrOD4zlx2p-NvYYypca1Z2s4dlUZPu9I0s130_assertion description "[DKK1 methylation was found in 14 (29.8%) patients, and more frequently in those with CBF leukaemia (6 of 12 patients), than in those with acute promyelocytic leukaemia (APL) (0 of 6 patients) (P = 0.03).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624116.RAb4fmOs9XqlrOD4zlx2p-NvYYypca1Z2s4dlUZPu9I0s130_provenance.
- NP866331.RAPcoxTtltQ9vBJRL5LXIbbz8Gjnmmkcakqi8Q66sGXig130_assertion description "[DKK1 methylation was found in 14 (29.8%) patients, and more frequently in those with CBF leukaemia (6 of 12 patients), than in those with acute promyelocytic leukaemia (APL) (0 of 6 patients) (P = 0.03).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP866331.RAPcoxTtltQ9vBJRL5LXIbbz8Gjnmmkcakqi8Q66sGXig130_provenance.